BRTX Stock Forecast 2025-2026
Distance to BRTX Price Targets
BRTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching BioRestorative (BRTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BRTX and similar high-potential opportunities.
Latest BRTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, BRTX has a bullish consensus with a median price target of $13.00 (ranging from $8.00 to $18.00). Currently trading at $1.91, the median forecast implies a 580.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Aschoff at Roth MKM, projecting a 842.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BRTX Analyst Ratings
BRTX Price Target Range
Latest BRTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BRTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 14, 2024 | Roth MKM | Jonathan Aschoff | Buy | Maintains | $18.00 |
| Jun 12, 2024 | Roth MKM | Jonathan Aschoff | Buy | Maintains | $15.00 |
| Aug 14, 2023 | Roth MKM | Jonathan Aschoff | Buy | Reiterates | $15.00 |
| Dec 7, 2022 | Roth Capital | Jonathan Aschoff | Buy | Initiates | $15.00 |
| Sep 28, 2022 | Maxim Group | Michael Okunewitch | Buy | Initiates | $6.00 |
| Dec 1, 2021 | Roth Capital | Elemer Piros | Buy | Initiates | $37.00 |
Biorestorative Therapies Inc. (BRTX) Competitors
The following stocks are similar to BioRestorative based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biorestorative Therapies Inc. (BRTX) Financial Data
Biorestorative Therapies Inc. has a market capitalization of $13.63M with a P/E ratio of -0.8x. The company generates $377,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +660.9% quarter-over-quarter, while maintaining an operating margin of -979.0% and return on equity of -84.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Biorestorative Therapies Inc. (BRTX) Business Model
About Biorestorative Therapies Inc.
Develops therapeutic products using cell and tissue technologies.
The company generates revenue through the research and development of innovative stem cell therapies aimed at treating chronic diseases. By collaborating with healthcare providers and research institutions, it enhances its research capabilities and expands potential market applications for its products.
Biorestorative Therapies Inc. focuses on addressing unmet medical needs, particularly in regenerative medicine, which positions it within a growing sector of the biopharmaceutical industry. Its work on conditions like chronic lumbar disc disease, obesity, and diabetes suggests a commitment to improving quality of life for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
11
CEO
Mr. Lance Alstodt
Country
United States
IPO Year
2020
Website
www.biorestorative.comBiorestorative Therapies Inc. (BRTX) Latest News & Analysis
BRTX-100 is the first stem cell product approved for evaluation in treating cervical degenerative disc disease.
BRTX-100's unique status as the first stem cell product for cervical degenerative disc disease may lead to significant market potential and competitive advantage, impacting investment decisions.
BioRestorative Therapies, Inc. (BRTX) will host a conference call on February 27, 2025, at 10:30 AM EST to discuss updates on its regenerative medicine pipeline.
The rescheduled conference call indicates a significant update on BioRestorative's pipeline, which may influence stock performance and investor sentiment regarding its regenerative medicine prospects.
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
1 month agoBioRestorative Therapies (BRTX) received FDA Fast Track designation for BRTX-100, targeting chronic lumbar disc disease, following positive Phase 2 safety and efficacy data.
Fast Track designation for BRTX-100 signals potential quicker market entry and approval, addressing a significant unmet need, which could boost BioRestorative's stock value.
BioRestorative Therapies, Inc. announced cGMP manufacturing processes and expects protection for its developments until April 29, 2040.
The announcement of cGMP manufacturing processes and extended protection until 2040 suggests potential for long-term revenue growth and competitive advantages, positively impacting investor sentiment.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) will hold its Q3 2024 earnings conference call on November 13, 2024, at 4:30 PM ET, discussing results and BRTX-100 Phase 2 study data.
BioRestorative's Q3 earnings call will reveal financial performance and updates on the BRTX-100 Phase 2 study, crucial for assessing future growth potential and investment viability.
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
4 months agoThe new development permits the processing of allogeneic donor tissue, including stem cells, for medical research purposes.
Advancements in processing allogeneic donor tissue can drive innovation in medical research, potentially leading to new therapies and growth opportunities in biotech investments.
Frequently Asked Questions About BRTX Stock
What is Biorestorative Therapies Inc.'s (BRTX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Biorestorative Therapies Inc. (BRTX) has a median price target of $13.00. The highest price target is $18.00 and the lowest is $8.00.
Is BRTX stock a good investment in 2025?
According to current analyst ratings, BRTX has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BRTX stock?
Wall Street analysts predict BRTX stock could reach $13.00 in the next 12 months. This represents a 580.6% increase from the current price of $1.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biorestorative Therapies Inc.'s business model?
The company generates revenue through the research and development of innovative stem cell therapies aimed at treating chronic diseases. By collaborating with healthcare providers and research institutions, it enhances its research capabilities and expands potential market applications for its products.
What is the highest forecasted price for BRTX Biorestorative Therapies Inc.?
The highest price target for BRTX is $18.00 from Jonathan Aschoff at Roth MKM, which represents a 842.4% increase from the current price of $1.91.
What is the lowest forecasted price for BRTX Biorestorative Therapies Inc.?
The lowest price target for BRTX is $8.00 from at , which represents a 318.8% increase from the current price of $1.91.
What is the overall BRTX consensus from analysts for Biorestorative Therapies Inc.?
The overall analyst consensus for BRTX is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are BRTX stock price projections?
Stock price projections, including those for Biorestorative Therapies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
